- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Dr Ira Klein: Biosimilars and the Cost of Care
Ira Klein, MD, senior director of health care quality strategy for the strategic customer group at Johnson & Johnson Health Care Services, explains how biosimilars will help to control costs.
Transcript:
Do you see biosimilar treatments as playing a role in controlling the cost of care?
I think we’ve already seen biosimilars act as a cost-leveraging mechanism. If you look at the average sales price of original anti—tumor necrosis factor drugs, and you look at the entrance of biosimilars into the marketplace, you can see a definite competitive trend, so there is a lot of competition in this space and that is causing [average sales prices, ASPs] to go down. I think that as the field continues to grow, you’ll see more of this.
I would say that our position is that patients who are on a particular agent should remain on that agent if they’re getting efficacious therapy, because "biosimilar" does not mean "same molecule." For new starts, I think that it should be a level playing field and the competition should be on the basis of both price and service delivery as well as known outcomes. However, I think that on existing therapy, our first duty is to keep the patient safe. But overall, in this field, biosimilars will act in a market force the way other market forces have caused competition to adjust price. We’re seeing that in the marketplace and we think that’s good for the American public.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
